Related Announcements

RFA-CA-22-001 - Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

RFA-CA-22-003 - Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a pre-application webinar on January 25, 2022 from 1:00 p.m. – 2:00 p.m. (ET) for Funding Opportunity Announcements (FOAs) RFA-CA-22-001 and RFA-CA-22-003 associated with NCI’s Innovative Molecular Analysis Technologies (IMAT) program. This pre-application webinar will be focused on introducing the R61 grant mechanism utilized by these funding opportunities. The R61 is replacing the R21 grant mechanism in the IMAT program to support projects in the earliest stage of technology development.

NCI staff involved in these FOAs will be explaining the grant mechanisms, objectives, and responsiveness criteria for the FOAs and answering questions from webinar attendees.

Note: Questions about the scope of the FOAs will be addressed during the webinar; however, questions about investigators’ specific study aims will not be addressed in the webinar.

Webinar pre-registration:

https://cbiit.webex.com/cbiit/j.php?RGID=r2134cbaf811ca7896f4bb004ef237d0d

Participants are encouraged to join early to ensure connectivity.

Participation in this webinar, while encouraged for potential applicants, is optional and not required for application submission.

Inquiries

Please direct all inquiries to:

Kelly Crotty, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-760-7997
Email: [email protected]